Table S2 from Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment
Although artemisinin combination therapies have succeeded in reducing the global burden of malaria, multidrug resistance of the deadliest malaria parasite, Plasmodium falciparum, is emerging worldwide
Global histone deacetylase inhibitors market size is expected to reach $1.64 billion by 2028 at a rate of 8.0%, segmented as by classification, class i histone deacetylases (hdacs), class ii histone d
X-linked myotubular myopathy (XLMTM) is a fatal neuromuscular disorder caused by loss of function mutations in MTM1 . At present, there are no directed therapies for XLMTM, and incomplete understandin
Breast cancer is one of the most lethal cancers in women, and its resistance to chemotherapy remains a challenging problem. Histone deacetylases inhibitors (HDACIs) are a promising therapeutic tool fo
These data are the original data used to produce the figures, tables, and supplemental information for the manuscript "Epigenetic small molecule screening identifies a new HDACi compound for ameliorat
